9:00 am Chair’s Opening Remarks

9:10 am Kick-off Panel Discussion

Synopsis

  • Overview of recent encouraging clinical case studies across the industry – what are the treatments that are around the corner promising results?
  • What has Biogen’s aducanumab story taught us?
  • What new research has been revealed to shine light on the mechanisms that are driving neurodegenerative pathology?
  • What are the learnings from a more acute neurological injury like a stroke or a TBI or Guillain-Barre syndrome?
  • Is there space for all of these different modalities out there? Where should we concentrate our efforts?

10:00 am Speed Networking

1:00 pm Lunch Break

2:00 pm Targeting Myeloid Immune Cell Dysfunction to Revolutionize Neurodegenerative Treatment – From Discovery to the Clinic

2:30 pm Targeting Amyloid Beta for Alzheimer’s Disease

  • Michele Vendruscolo Professor & CSO, Cambridge University Centre for Misfolding Diseases & Wren Therapeutics

3:00 pm ALZ-801 Phase 3 Program: A Targeted Oral Disease Modifying Therapy for Alzheimer’s Disease

3:30 pm Clinical Case Study: Exploring AL001 for the Treatment of FTD

4:00 pm Live Q&A With Your Expert Speakers

4:30 pm Networking Break

6:40 pm Highlights From Both the Discovery & Translational Streams

6:50 pm Chair’s Closing Remarks